Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Multicenter Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Patients With Relapsed and/or Refractory Multiple Myeloma

NCT02917941 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02917941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02917941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Multicenter Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Patients With Relapsed and/or Refractory Multiple Myeloma
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Completed
Start date
November 1, 2016
Completion date
August 31, 2019
Enrollment
34 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and/or refractory multiple myeloma